- Home
- NBY vs BGB Comparison
NBY vs BGB Comparison
Compare NBY & BGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- BGB
- Stock Information
- Founded
- NBY 2000
- BGB 2012
- Country
- NBY United States
- BGB United States
- Employees
- NBY N/A
- BGB N/A
- Industry
- NBY
- BGB Trusts Except Educational Religious and Charitable
- Sector
- NBY
- BGB Finance
- Exchange
- NBY Nasdaq
- BGB Nasdaq
- Market Cap
- NBY 3.5M
- BGB 537.8M
- IPO Year
- NBY 2007
- BGB N/A
- Fundamental
- Price
- NBY $0.62
- BGB $12.18
- Analyst Decision
- NBY Strong Buy
- BGB
- Analyst Count
- NBY 1
- BGB 0
- Target Price
- NBY $0.85
- BGB N/A
- AVG Volume (30 Days)
- NBY 32.4K
- BGB 154.6K
- Earning Date
- NBY 08-12-2025
- BGB 01-01-0001
- Dividend Yield
- NBY N/A
- BGB 9.75%
- EPS Growth
- NBY N/A
- BGB N/A
- EPS
- NBY 0.57
- BGB N/A
- Revenue
- NBY $9,781,000.00
- BGB N/A
- Revenue This Year
- NBY $23.91
- BGB N/A
- Revenue Next Year
- NBY $32.05
- BGB N/A
- P/E Ratio
- NBY $1.34
- BGB N/A
- Revenue Growth
- NBY 20.52
- BGB N/A
- 52 Week Low
- NBY $0.36
- BGB $10.40
- 52 Week High
- NBY $2.45
- BGB $11.97
- Technical
- Relative Strength Index (RSI)
- NBY 56.70
- BGB 62.75
- Support Level
- NBY $0.58
- BGB $12.01
- Resistance Level
- NBY $0.64
- BGB $12.10
- Average True Range (ATR)
- NBY 0.03
- BGB 0.06
- MACD
- NBY 0.00
- BGB 0.01
- Stochastic Oscillator
- NBY 62.38
- BGB 89.66
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About BGB Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest
Blackstone Strategic Credit Fund is a closed-end term fund. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.